Two randomized Phase 3 trials with second generation FLT3 inhibitors were recently conducted in R/R AML patients with FLT3 mutations (gilteritinib) or FLT3‐ITD only mutations (quizartinib) [70, 71]. Here, FLT3 is linked to acute myeloid leukemia.